Yang Yang, PhD
Associate Professor of Obstetrics, Gynecology and Reproductive SciencesDownloadHi-Res Photo
Cards
Appointments
Contact Info
About
Copy Link
Titles
Associate Professor of Obstetrics, Gynecology and Reproductive Sciences
Biography
Ph.D., Microbiology, Nankai University, China.
Postdoctoral training, Tumor Biology, Yale University.
Last Updated on May 18, 2025.
Appointments
Obstetrics, Gynecology & Reproductive Sciences
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- PhD
- Nankai University (2009)
Research
Copy Link
Overview
Tumor initiation; Chemoresistance
Medical Research Interests
Ovarian Neoplasms
ORCID
0000-0002-0522-9053
Research at a Glance
Yale Co-Authors
Frequent collaborators of Yang Yang's published research.
Publications Timeline
A big-picture view of Yang Yang's research output by year.
Research Interests
Research topics Yang Yang is interested in exploring.
Alessandro Santin, MD
Stefania Bellone, PhD
Blair McNamara, MD
Tobias Hartwich, PhD
Levent Mutlu
Former YSMCem Demirkiran, MD
67Publications
2,591Citations
Ovarian Neoplasms
Publications
2026
Rates of hypertensive disorders of pregnancy among patients with placenta accreta spectrum
Sinnott C, Alshowaikh K, Culhane J, Lundsberg L, Kolesnyk V, Partridge C, Giuliano S, Yang-Hartwich Y, Abdel-Razeq S, Grechukhina O. Rates of hypertensive disorders of pregnancy among patients with placenta accreta spectrum. American Journal Of Obstetrics & Gynecology MFM 2026, 8: 101919. PMID: 42091294, DOI: 10.1016/j.ajogmf.2026.101919.Peer-Reviewed Original ResearchGRP78 Selective Inhibitors From a Direct‐to‐Biology Strategy
Zhu X, Trindl C, Li Q, Ye H, Alexander L, Huang D, Wei Y, Trieu V, Stansfield B, Ooi A, Yang‐Hartwich Y, Zhang D, Chapman E. GRP78 Selective Inhibitors From a Direct‐to‐Biology Strategy. Angewandte Chemie International Edition 2026, 65: e23960. PMID: 42023476, DOI: 10.1002/anie.202523960.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsUnfolded protein responseProtein homeostasisSubstrate binding pocketCancer cellsA549 lung cancer cellsProteostasis machineryLung cancer cellsSubstrate bindingProtein responseHeat shock proteinsGRP78 inhibitionHSP70 familySecretory systemGRP78Binding pocketMode of actionProteostasisShock proteinsHSP70sPrincipal regulatorProteinCancer therapeuticsHSP70HomeostasisCellsGRP78 Selective Inhibitors From a Direct‐to‐Biology Strategy
Zhu X, Trindl C, Li Q, Ye H, Alexander L, Huang D, Wei Y, Trieu V, Stansfield B, Ooi A, Yang‐Hartwich Y, Zhang D, Chapman E. GRP78 Selective Inhibitors From a Direct‐to‐Biology Strategy. Angewandte Chemie 2026, 138 DOI: 10.1002/ange.202523960.Peer-Reviewed Original ResearchConceptsUnfolded protein responseProtein homeostasisSubstrate binding pocketCancer cellsA549 lung cancer cellsProteostasis machineryLung cancer cellsSubstrate bindingProtein responseHeat shock proteinsHSP70 familyGRP78 inhibitionSecretory systemGRP78Binding pocketShock proteinsMode of actionProteostasisHSP70sPrincipal regulatorProteinCancer therapeuticsHSP70HomeostasisCellsIdentification of Maternal Serum Longitudinal Signatures Through Profiling of 96 Cytokines
Kolesnyk V, Sinnott C, Hartwich T, Gandhi F, Culhane J, Lundsberg L, Abdel-Razeq S, Mansolf M, Novo S, Grechukhina O, Yang-Hartwich Y. Identification of Maternal Serum Longitudinal Signatures Through Profiling of 96 Cytokines. Life 2026, 16: 710. PMID: 42195265, PMCID: PMC13208128, DOI: 10.3390/life16050710.Peer-Reviewed Original ResearchConceptsHealthy pregnancyCytokine patternSerum cytokine patternManagement of pregnancyMaternal serum samplesSerum biomarker panelEarly detectionSerum samplesPathological conditionsNormal pregnancyCytokine scoreImmune signaturesImmune profileMultiplex ELISACytokine landscapeDetection of pathological conditionsBiomarker panelPregnancyUnsupervised principal component analysisProperties in vitroImmune adaptationCytokinesClinical signsSerumPreeclampsiaIntegrated mutational landscape analysis of endometrial stromal sarcoma
Hartwich T, Choi S, Hwang A, Bellone S, Palmieri L, Seo H, Kim T, Hong J, Krakstad C, Trovik J, Stefansson I, Haugland H, Greenman M, Ettorre V, Ottum S, Demirkiran C, Yang-Hartwich Y, Buza N, Hui P, Lopez S, Cormio G, Ramunno M, Zito A, Perrone E, Fagotti A, Fanfani F, Santoro A, Ravaggi A, Bignotti E, Odicino F, Ardighieri L, Ratner E, Angioli R, Perrone G, Luvero D, Conca B, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of endometrial stromal sarcoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2026, 123: e2531105123. PMID: 41591910, PMCID: PMC12867622, DOI: 10.1073/pnas.2531105123.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEndometrial stromal sarcomaHG-ESSStromal sarcomaLG-ESSFrequent lossMolecular basisHigh-gradeLow-gradePrediction of immunotherapy responseLoss of cell cycle regulationCell cycle regulationComplex DNA rearrangementsRare uterine malignancyCombination of MEKMutational landscape analysisDriver of malignancyTargeted treatment strategiesWhole genomeDNA rearrangementsFAK inhibitionTranscriptome sequencingWhole exomeGenetic landscapeChromosomal gainsRegulated genesPrenatal overdiagnosis of placenta accreta spectrum: associated factors and perinatal outcomes
Grechukhina O, Sinnott C, Alshowaikh K, Culhane J, Lundsberg L, Partridge C, Yang-Hartwich Y, Bahtiyar M, Abdel-Razeq S. Prenatal overdiagnosis of placenta accreta spectrum: associated factors and perinatal outcomes. American Journal Of Obstetrics & Gynecology MFM 2026, 8: 101850. PMID: 41513313, DOI: 10.1016/j.ajogmf.2025.101850.Commentaries, Editorials and Letters
2025
Antibody Generation Using Cancer‐Derived Small Extracellular Vesicles (sEVs): A Platform for Targeted Cancer Therapy and Potential Personalized Applications
Firouzi M, Kang C, Ren X, Jung W, Abushukair H, Hartwich T, Ramesh R, Yoon J, Yang‐Hartwich Y, Oh T, Kim D. Antibody Generation Using Cancer‐Derived Small Extracellular Vesicles (sEVs): A Platform for Targeted Cancer Therapy and Potential Personalized Applications. Small 2025, 22: e06918. PMID: 41311345, DOI: 10.1002/smll.202506918.Peer-Reviewed Original ResearchAltmetricConceptsTargeted cancer therapySmall extracellular vesiclesOVCAR-8Cancer therapyCancer-derived small extracellular vesiclesHuman ovarian carcinoma cell linesOvarian carcinoma cell linesCancer cell-specific targetingTumor-bearing miceTumor-targeting monoclonal antibodiesTumor-targeted therapyExtracellular vesiclesOVCAR-8 cellsCell-specific targetingCarcinoma cell linesEffective targeting ligandCancer-derivedSolid tumorsImmune activationNon-targeting controlPreclinical studiesTumor growthTumor accumulationPersonalized oncologyImmune responseIDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers
Zhang X, Xiao Q, Zeng L, Hashmi F, Sato K, Hartwich T, Mansolf M, Yang-Hartwich Y, Su X. IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers. Nature Chemical Biology 2025, 22: 379-391. PMID: 41023404, PMCID: PMC12825998, DOI: 10.1038/s41589-025-02031-x.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCAR-TChimeric antigen receptor (CAR)-T cell therapyCAR-T therapyCancer cells in vitroRelease of cytotoxic factorsCAR-T functionSolid tumor modelsAbsence of antigenLow antigen expressionCells in vitroMembrane-proximal signalingAntigen expressionAntigen sensitizationAntitumor effectCell therapyTumor modelIntractable cancerCytotoxic factorKilling activityBlood cancerCancerCancer targetLow antigenicityTherapyEfficacyPreclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmFemaleFocal Adhesion Kinase 1FulvestrantHumansMiceMice, SCIDOvarian NeoplasmsProtein Kinase InhibitorsReceptors, EstrogenXenograft Model Antitumor AssaysConceptsPatient-derived tumor xenograftTriple combinationFocal adhesion kinasePreclinical efficacyAromatase inhibitorsClinical evaluationEstrogen receptor (ER)-positiveAcquired resistance to chemotherapyOvarian cancer animal modelEstrogen receptor degrader fulvestrantPatients wild-typeVS-4718Cancer animal modelTumor growth inhibitionLimited treatment optionsResistance to chemotherapyP-ERK levelsFocal adhesion kinase inhibitorMedian survivalRare tumorOvarian carcinomaRecurrence rateTumor xenograftsTreatment optionsFulvestrantTET3 is a common epigenetic immunomodulator of pathogenic macrophages
Liu B, Dai Y, Wang Z, Song J, Du Y, Lv H, Bellone S, Yang Y, Kennedy A, Zhang S, Venkatachalapathy M, Surovtseva Y, Wang P, Carmichael G, Taylor H, Zhang X, Li D, Huang Y. TET3 is a common epigenetic immunomodulator of pathogenic macrophages. Journal Of Clinical Investigation 2025, 135: e194879. PMID: 40794443, PMCID: PMC12578387, DOI: 10.1172/jci194879.Peer-Reviewed Original ResearchThis study investigates the role of TET3 in promoting pathogenic macrophages across chronic inflammatory diseases, and shows that selectively eliminating TET3-overexpressing macrophages (“Toe-Macs”) can mitigate disease progression in conditions like MASH, NSCLC, and endometriosis.
Academic Achievements & Community Involvement
Copy Link
Honors
honor Department of Defense Ovarian Cancer Academy Award — Early-Career Investigator
08/01/2015National AwardDepartment of DefenseDetailsUnited Stateshonor Marsha Rivkin Ovarian Cancer Research Bridge Fund Award
06/01/2015International AwardMarsha Rivkin Ovarian Cancer Research CenterDetailsUnited Stateshonor American Association of Cancer Research Women in Cancer Research Scholar Award
04/14/2014International AwardAmerican Association of Cancer ResearchDetailsUnited Stateshonor Ovarian Cancer Research Ann Schreiber Program of Excellence Award
03/01/2014International AwardOvarian Cancer Research FundDetailsUnited States
News & Links
Copy Link
Media
News
- September 29, 2025
New Toolset by Yale Researchers Boosts Efficacy of CAR-T Cells Targeting Blood and Solid Cancers
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- April 01, 2024
Yale Cancer Center Experts, Scientists to Share Vision and Research at Leading Conference
- January 19, 2024Source: Yale Daily News
Yale scientists look to hearing loss to detect Alzheimer’s early
Get In Touch
Copy Link
Contacts
Locations
LSOG 205a
Academic Office
Farnam Memorial Building (330 Cedar)
330 Cedar Street
New Haven, CT 06510